- By ICR Secretariat
- Posted Tuesday, February 21, 2017
EMA reviews Actelion PAH drug after patient deaths
The European Medicines Agency has launched a safety review of Actelion Pharma's pulmonary arterial hypertension medicine Uptravi (selexipag) to investigate the deaths of 5 patients taking the drug in France.
Image credit: Actelion